John Reed to join Roche Pharma Research and Early Development

Takes up role as head of pRED in April

Swiss pharmaceutical manufacturer Roche has appointed John Reed as head of Roche Pharma Research and Early Development (pRED). The Genentech Research and Early Development organisation (gRED), based in South San Francisco, is not affected by this management change.

Reed will be based in Basel and take up his new role on 2 April, reporting to Severin Schwan, CEO of the Roche Group.

Schwan said Reed’s broad scientific and medical background means he is ‘ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics’.

Mike Burgess, currently interim head of pRED, has decided to leave the company.

Prior to joining Roche, Reed was CEO at Sanford-Burnham Medical Research Institute in La Jolla, California. He is a biomedical researcher with a focus on cancer, neuroprotection, autoimmunity, and other diseases.

You may also like

Research & Development

PhoreMost partners with Roche on multi-project drug target collab

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER
Research & Development

Lab standardisation: working smarter to improve patient outcomes

We’re living in a pivotal time for healthcare, reports Benjamin Lilienfeld, LifeCycle Leader at Roche Diagnostics Solutions. An advanced understanding of diseases, innovative techniques and treatments, a dizzying array of new technologies and a growing population of empowered and knowledgeable patients and caregivers have, together, made healthcare systems increasingly complex
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Research & Development

Exscientia initiates sixth AI drug discovery partnership

Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Media

Worldwide prescription drug sales accelerate to $1.2 trillion by 2024

Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market
Research & Development

Unified data model to facilitate data sharing and accelerate life science research

Elsevier will donate its unified data model (UDM) to The Pistoia Alliance, ensuring data is a common language in the research community, removing research bottlenecks and barriers to collaboration
Research & Development

MIMETAS develops high-throughput gut-on-a-chip technology

MIMETAS, in collaboration with the pharmaceutical company Roche, has developed a novel organ-on-a-chip system that supports evaluation of intestinal permeability in perfused 3-D gut tubules in high throughput under exposure to pharmacological compounds, the results of the research were published in <i>Nature Communications</i>
Subscribe now